EFFICACY OF COMBINATION FLUDARABINE AND ALEMTUZUMAB IN PATIENTS WITH RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA

被引：0
|
作者：
Zagoskina, T. [1 ]
Zotina, E. [1 ]
Malykh, O. [1 ]
机构：
[1] Kirov Res Inst Hematol & Blood Transfus, Kirov, Russia
来源：
HAEMATOLOGICA | 2012年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0752
引用
收藏
页码：305 / 305
页数：1
相关论文
共 50 条
  • [21] Phase II Trial of Subcutaneous Alemtuzumab in Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia
    不详
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 (03): : 202 - 203
  • [22] Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia
    Ferrajoli, Alessandra
    Wierda, William G.
    LaPushin, Ruth
    O'Brien, Susan M.
    Faderl, Stefan
    Browning, Mary L.
    Keating, Michael J.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2008, 80 (04) : 296 - 298
  • [23] Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia
    Wierda, W
    O'Brien, S
    Wen, S
    Faderl, S
    Garcia-Manero, G
    Thomas, D
    Do, KA
    Cortes, J
    Koller, C
    Beran, M
    Ferrajoli, A
    Giles, F
    Lerner, S
    Albitar, M
    Kantarjian, H
    Keating, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (18) : 4070 - 4078
  • [24] Efficacy Of Bendamustine and Rituximab In Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
    Kataeva, Elena
    Golenkov, Anatoly
    Triphonova, Elena
    Dudina, Galina
    Mitina, Tatyana
    Lutskaya, Tatyana
    Vysotskaya, Ludmila
    Chernykh, Yulliya
    Zakharov, Sergey
    BLOOD, 2013, 122 (21)
  • [25] Multicenter study of subcutaneous alemtuzumab administered at reduced dose in patients with fludarabine-relapsed/refractory chronic lymphocytic leukemia: final analysis
    Fernando Bezares, Raimundo
    Stemelin, German
    Diaz, Alicia
    Argentieri, Daniel
    Lanari Zubiaur, Emilio
    Garay, Guy
    Bartomioli, Miguel
    Ryser, Ricardo
    Milone, Gustavo
    LEUKEMIA & LYMPHOMA, 2011, 52 (10) : 1936 - 1941
  • [26] An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia
    Montillo, Marco
    Tedeschi, Alessandra
    Petrizzi, Valeria Belsito
    Ricci, Francesca
    Crugnola, Monica
    Spriano, Mauro
    Spedini, Pierangelo
    Ilariucci, Fiorella
    Uziel, Lilj
    Attolico, Immacolata
    Vismara, Eleonora
    De Blasio, Angelo
    Zaccaria, Alfonso
    Morra, Enrica
    BLOOD, 2011, 118 (15) : 4079 - 4085
  • [27] Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL)
    Montillo, Marco
    Ricci, Francesca
    Miqueleiz, Sara
    Tedeschi, Alessandra
    Morra, Enrica
    BIOLOGICS-TARGETS & THERAPY, 2008, 2 (01): : 41 - 52
  • [28] Fludarabine, Cyclophosphamide, and Alemtuzumab (FCC) In Relapsed/Refractory Patients with B-Cell Chronic Lymphocytic Leukemia (CLL): Final Report of the Italian Study
    Montillo, Marco
    Tedeschi, Alessandra
    Ricci, Francesca
    Zaccaria, Alfonso
    Crugnola, Monica
    Spriano, Mauro
    Spedini, PierAngelo
    Ilariucci, Fiorella
    Uziel, Lilj
    Attolico, Immacolata
    De Blasio, Angelo
    Vismara, Eleonora
    Morra, Enrica
    Petrizzi, Valeria Belsito
    BLOOD, 2010, 116 (21) : 595 - 596
  • [29] Improved survival in patients with relapsed - Refractory chronic lymphocytic leukemia (CLL) treated with fludarabine, cyclophosphamide, and rituximab (FCR) combination.
    Wierda, W
    O'Brien, S
    Faderl, S
    Ferrajoli, A
    Lerner, S
    Wang, XM
    Thomas, D
    Garcia-Manero, G
    Cortes, J
    Kantarjian, H
    Keating, M
    BLOOD, 2003, 102 (11) : 110A - 110A
  • [30] A Phase 2 Trial of Fludarabine Combined With Subcutaneous Alemtuzumab for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia
    Flowers, Christopher R.
    Brown, Jennifer R.
    Rosenthal, Hilary
    Stock, Wendy
    Katzen, Harvey I.
    Cohen, Jonathon B.
    Sinha, Rajni
    Lakhanpal, Shailendra
    Leis, Jose F.
    Waller, Edmund K.
    Jaye, David L.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (11): : 694 - 698
12345